
Lecanemab Can Delay Alzheimer’s 8 Years: New Data, New Hope
New long-term data suggests lecanemab could delay the shift from mild memory loss to moderate Alzheimer’s by up to eight years—offering families precious time and renewed hope.

New long-term data suggests lecanemab could delay the shift from mild memory loss to moderate Alzheimer’s by up to eight years—offering families precious time and renewed hope.

Leqembi is one of the first Alzheimer’s treatments proven to slow decline. A new MRI study helps explain what it can—and cannot—do in the brain’s early months, offering clearer expectations for caregivers.

NEW RESEARCH: A diabetes medication already helping millions, called Jardiance, improves memory, strengthens blood flow, and supports overall brain health in pre- and early Alzheimer’s.

IMAGINE THIS: Instead of going to an infusion center for treatment, you can switch to a weekly injection at home. That’s now a reality for many Alzheimer’s patients.

PRODUCT OF THE WEEK: Caregivers love this pill box, as do patients and professionals. Simply fill it once a month. Roomy, simple, ingenious.

Caring for someone with Alzheimer’s is demanding enough. Now, instead of traveling for hours of infusions, families can turn to Leqembi IQLIK—a once-weekly injection approved by the FDA that makes treatment simpler, safer, and closer to home.

They’re not just pills—they’re precision infusions designed to slow Alzheimer’s at its source. See UCLA’s cutting-edge Amyloid Immunotherapy Care Program, and what it feels like to begin treatment with Leqembi (lecanemab) and Kisunla (donanemab).

Leqembi, the first Alzheimer’s-modifying drug, is a giant step forward—but how many people are getting it, and what does it really cost the average American? We dig into the numbers, the barriers, and the path forward.

FDA approves a newly recommended dosing schedule for Kisunla (Donanemab). It’s significantly safer due to lowered ARIA-E rates, which has been the main problem with these drugs.

Lecanemab (marketed as Leqembi) is today’s top Alzheimer’s drug. Why does equitable access to this drug remain a significant challenge? What needs to be done?

Watch the huge “Giving Voice Chorus” come alive and rise above Alzheimer’s. Get inspired by the music that Alzheimer’s can’t shake.

TEEPA CARE VIDEO:
Teepa Snow explains what to expect as dementia takes over the brain. Learn how our fascinating brains work and affect our behavior.

Can a happier frame of mind help overcome aging’s cognitive decline? Ohio State University scientists share meaningful insights from their study.

Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?

An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?

Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!

It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.
No spam, only news and updates.



We use cookies and similar technologies to improve your experience, understand how our content is used, and support relevant advertising that helps keep Alzheimer’s Weekly free to readers. You can choose to accept, deny, or manage your preferences at any time. Declining certain cookies may affect features such as embedded videos, comments, and personalized advertising.